Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HA-1 TCR T cells |
| Synonyms | |
| Therapy Description |
HA-1 TCR T cells are CD8 and CD4 positive T-cells that have been engineered to express a T-cell receptor (TCR) that targets HA-1, potentially resulting in increased immune response against HA-1-expressing tumor cells (PMID: 29051183). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HA-1 TCR T cells | CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR | HA-1 TCR T cells are CD8 and CD4 positive T-cells that have been engineered to express a T-cell receptor (TCR) that targets HA-1, potentially resulting in increased immune response against HA-1-expressing tumor cells (PMID: 29051183). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03326921 | Phase I | Cyclophosphamide + Fludarabine HA-1 TCR T cells | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | Recruiting | USA | 0 |